alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 21.1
 SUBSIDIARIES
 Jurisdiction OfName
    
    OrganizationClare Canada, Ltd.
    
    CanadaClare Capital, Inc.
    
    DelawareClare Components, Inc.
    
    DelawareClare Electronics, Inc.
    
    DelawareClare France S.A.R.L.
    
    FranceClare, Inc.
    
    MassachusettsClare Instruments, Inc.
    
    DelawareClare Instruments (U.S.), Inc.
    
    DelawareClare Micronix Integrated Systems, Inc.
    
    CaliforniaClare Services, Inc.
    
    DelawareClare Systems, Inc.
    
    DelawareClare Technologies, Inc.
    
    DelawareClare Technologies (Taiwan), Inc.
    
    TaiwanC.P. Clare Electronics GmbH
    
    GermanyC.P. Clare Foreign Sales Corporation
    
    U.S. Virgin IslandsC.P. Clare International N.V.
    
    BelgiumDirected Energy, Inc.
    
    ColoradoIXYS Berlin GmbH
    
    GermanyIXYS Buckeye, LLC
    
    DelawareIXYS Caymans L.P.
    
    Cayman Islands B.W.I.IXYS CH GmbH
    
    SwitzerlandIXYS Holdings Ltd.
    
    United KingdomIXYS Korea Ltd.
    
    South KoreaIXYS Long Beach, Inc.
    
    CaliforniaIXYS Semiconductor, B.V.
    
    NetherlandsIXYS Semiconductor GmbH
    
    GermanyIXYS Semiconductor, Ltd.
    
    South KoreaIXYS UK Ltd.
    
    United KingdomIXYS Unterstuetzungseinrichtung GmbH
    
    GermanyIXYS USA, Inc.
    
    DelawareMicrowave Technology, Inc.
    
    CaliforniaWestcode Industries Ltd.
    
    United KingdomWestcode Semiconductors, Ltd.
    
    United Kingdom
§ 1271.60 What quarantine and other requirements apply before the donor-eligibility determination is complete? ( a ) *Quarantine.* You must keep an HCT/P in quarantine, as defined in § 1271.3(q), until completion of the donor-eligibility determination required by § 1271.50. You must quarantine semen from anonymous donors until the retesting required under § 1271.85(d) is complete.
( b ) *Identification of HCT/Ps in quarantine.* You must clearly identify as quarantined an HCT/P that is in quarantine pending completion of a donor-eligibility determination. The quarantined HCT/P must be easily distinguishable from HCT/Ps that are available for release and distribution.
( c ) *Shipping of HCT/Ps in quarantine.* If you ship an HCT/P before completion of the donor-eligibility determination, you must keep it in quarantine during shipment. The HCT/P must be accompanied by records: ( 1 ) Identifying the donor (e.g., by a distinct identification code affixed to the HCT/P container);
( 2 ) Stating that the donor-eligibility determination has not been completed; and
( 3 ) Stating that the product must not be implanted, transplanted, infused, or transferred until completion of the donor-eligibility determination, except under the terms of paragraph (d) of this section.
( d ) *Use in cases of urgent medical need.* ( 1 ) This subpart C does not prohibit the implantation, transplantation, infusion, or transfer of an HCT/P from a donor for whom the donor-eligibility determination is not complete if there is a documented urgent medical need for the HCT/P, as defined in § 1271.3(u).
( 2 ) If you make an HCT/P available for use under the provisions of paragraph (d)(1) of this section, you must prominently label it “NOT EVALUATED FOR INFECTIOUS SUBSTANCES,” and “ WARNING: Advise patient of communicable disease risks.” The following information must accompany the HCT/P: ( i ) The results of any donor screening required under § 1271.75 that has been completed;
( ii ) The results of any testing required under § 1271.80 or 1271.85 that has been completed; and
( iii ) A list of any screening or testing required under § 1271.75, 1271.80 or 1271.85 that has not yet been completed.
( 3 ) If you are the establishment that manufactured an HCT/P used under the provisions of paragraph (d)(1) of this section, you must document that you notified the physician using the HCT/P that the testing and screening were not complete.
( 4 ) In the case of an HCT/P used for an urgent medical need under the provisions of paragraph (d)(1) of this section, you must complete the donor-eligibility determination during or after the use of the HCT/P, and you must inform the physician of the results of the determination.
2007-1949.

#### State v. Blackburn.

Guernsey App. No. 06 CA 37, 2007-Ohio-4282. On motion for leave to file delayed appeal. Motion denied.

Moyer, C.J., and Pfeifer and Lundberg Stratton, JJ., dissent.
Exhibit
32.1





Certification
of Chief Executive Officer and Chief Financial Officer


Pursuant
to 18 U.S.C. Section 1350, as Adopted Pursuant To


Section
906 Of The Sarbanes-Oxley Act of 2002





In
connection with the Quarterly Report of Hancock Fabrics, Inc. (the “Hancock”) on
Form 10-Q for the period ended October 31, 2009 as filed with the Securities and
Exchange Commission on the date hereof (the “Report”), both, Jane F. Aggers,
President and Chief Executive Officer of Hancock and Robert W. Driskell,
Executive Vice President and Chief Financial Officer of Hancock, certify,
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley
Act of 2002, that to the best of their knowledge:





1. The
Report fully complies with the requirements of section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and





2. The
information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the
Corporation.




Date: 
December 3, 2009





/s/ Jane F. AggersJane
      F. AggersPresident
      and Chief Executive Officer/s/ Robert W. DriskellRobert
      W. DriskellExecutive
      Vice President andChief
      Financial Officer(Principal
      Financial Officer)
Exhibit 32.1

                  CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
                       PURSUANT TO 18 U.S.C. SECTION 1350


         In connection with the accompanying Quarterly Report on Form 10-QSB,
Amendment No. 2, of Velocity Asset Management Inc. for the three months ended
September 30, 2004, I, John C. Kleinert, Chief Executive Officer of Velocity
Asset Management, Inc. hereby certify pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best
of my knowledge and belief, that:

                  (1) such Quarterly Report on Form 10-QSB, Amendment No. 2, for
the three months ended September 30, 2004, fully complies with the requirements
of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


                  (2) the information contained in such Quarterly Report on Form
10-QSB for the three months ended September 30, 2004, fairly presents, in all
material respects, the financial condition and results of operations of Velocity
Asset Management, Inc.

                                          /s/ JOHN C. KLEINERT
                                          ------------------------------
                                          John C. Kleinert
                                          Chief Executive Officer



July 22, 2005


                                       27
### D ISTRICT 

### C OURT 

### O F 

### A PPEAL 

### O F 

### T HE 

### S TATE 

### O F 

### F LORIDA

F OURTH D ISTRICT

Y.R., a child

,

Appellant,

v.

STATE OF FLORIDA

, Appellee

.

No. 4D 22

- 318

[ March 22, 2023 ]

Appeal from the Circuit Court for the Fifteenth Judicial Circuit, Palm Beach County ; Cymonie S. Rowe , Judge; L.T. Case No. 21CJ000106AMB

.

Carey Haughwout, Public Defender, and Logan T. Mohs, Assistant Public Defender, West Palm Beach, for appellant.

Ashley Moody, Attorney General, Tallahassee, and Pablo Tapia, Assistant Attorney General, West Palm Beach, for appellee.

P ER C URIAM

.

Affirmed. See § 90.704, Fla. Stat. (2021) (“ The facts or data upon which an expert bases an opinion or inference may be those perceived by, or made known to, the expert at or before the trial. If the facts o r data are of a type reasonably relied upon by experts in the subject to support the opinion expressed, the facts or data need not be admissible in evidence. Facts or data that are otherwise inadmissible may not be disclosed to the [factfinder] by the proponent of the opinion or inference unless the court determines that their probative value in assisting the [factfinder] to evaluate the expert ’ s opinion substantially outweighs their prejudicial

effect. ”).

W ARNER
, G ERBER and L EVINE
, JJ., concur

.

* * *

Not final until disposition of timely filed motion for rehearing.
# ADDENDUM TO:

**DRAFT EPA NEW ENGLAND**  **REGIONAL CLIMATE ADAPTATION PLAN** 

**NOVEMBER 6, 2013**Update to p. 2 1:

The Connecticut Climate Change Preparedness Plan was finalized in July 2013. This final plan is accessible at http://www.ct.gov/deep/lib/deep/climatechange/connecticut_climate_preparedness_plan_201 1.pdf Update to p. 23 : Final Connecticut Climate Change Preparedness Plan, 2013, is accessible at: http://www.ct.gov/deep/lib/deep/climatechange/connecticut_climate_preparedness_plan_201 1.pdf The Impacts of Climate Change on Connecticut Agriculture, Infrastructure, Natural Resources and Public Health, 2010 is accessible at: http://www.ct.gov/deep/lib/deep/climatechang e/impactsofclimatechange.pdf Update to p. 6 5 , reference 67: Maine’s Climate Future: an Initial Assessment, 2009, is accessible at: http://climatechange.umaine.edu/files/Maines_Climate_Future.pdf
##### 



EXHIBIT 23.1

Consent of Independent Accountants

To Board of Directors
Front Range Capital Corporation

We consent to the use in the Form 10-QSB of Front Range Capital
Corporation for the quarterly period ended June 30, 2003 our report dated
August 5, 2003 relating to the consolidated balance sheet of Front Range
Capital Corporation and subsidiaries as of June 30, 2003 and the related
consolidated statements of income, comprehensive income and cash flows for the
three-month period and six-month periods then ended.



| | /s/ Fortner, Bayens, Levkulich & Co., P.C.
| | ------------------------------------------

Denver, Colorado
August 13, 2003
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7333 Engrossed in House (EH)]

<DOC>
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
118th CONGRESS
  2d Session
                                H. R. 7333

_______________________________________________________________________

                                 AN ACT

 
To name the Department of Veterans Affairs medical center in West Palm 
     Beach, Florida, as the ``Thomas H. Corey VA Medical Center''.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. NAME OF DEPARTMENT OF VETERANS AFFAIRS MEDICAL CENTER, WEST 
              PALM BEACH, FLORIDA.

     The Department of Veterans Affairs medical center in West Palm 
Beach, Florida, shall after the date of the enactment of this Act be 
known and designated as the ``Thomas H. Corey VA Medical Center''. Any 
reference to such medical center in any law, regulation, map, document, 
record, or other paper of the United States shall be considered to be a 
reference to the Thomas H. Corey VA Medical Center.

            Passed the House of Representatives July 22, 2024.

            Attest:

                                                                 Clerk.
118th CONGRESS

  2d Session

                               H. R. 7333

_______________________________________________________________________

                                 AN ACT

To name the Department of Veterans Affairs medical center in West Palm 
     Beach, Florida, as the ``Thomas H. Corey VA Medical Center''.
```
<PAGE>   1



HANCOCK FABRICS, INC.                                                EXHIBIT 11
COMPUTATION OF EARNINGS (LOSS) PER SHARE
(unaudited)
<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------
(dollars in thousands, except for
  per share amounts)                                     Thirteen Weeks Ended              Twenty-six Weeks Ended
                                                       -------------------------       -----------------------------
                                                        August 1,      August 2,         August 1,         August 2,
                                                          1999           1998              1999              1998

--------------------------------------------------------------------------------------------------------------------
<S>                                                 <C>              <C>               <C>               <C>
Primary earnings (loss) per share

  Net earnings (loss)                                     ($759)     $       442       $        345      $      2,549
                                                    ===========      ===========       ============      ============
  Weighted average number of common shares
   outstanding during period                         18,119,391       20,298,940         18,134,410        20,456,265
                                                    ===========      ===========       ============      ============

Basic earnings (loss) per share                          ($0.04)     $      0.02       $       0.02      $       0.12
                                                    ===========      ===========       ============      ============

Diluted earnings (loss) per share
  Net earnings (loss)                                     ($759)     $       442       $        345      $      2,549
                                                    ===========      ===========       ============      ============

  Weighted average number of common shares
   outstanding during period                         18,119,391       20,298,940         18,134,410        20,456,265

   Common stock equivalents                                   0          239,977                  0           337,422

   Contigently issuable shares                                0           56,203                  0            77,722
                                                    -----------      -----------       ------------      ------------

                                                     18,119,391       20,595,120         18,134,410        20,871,409
                                                    ===========      ===========       ============      ============

Diluted earnings (loss) per share                        ($0.04)     $      0.02       $       0.02      $       0.12
                                                    ===========      ===========       ============      ============

</TABLE>
<PAGE>
EXHIBIT 31.2

CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) OF THE SECURITIES EXCHANGE
ACT OF 1934, AS AMENDED

I, Alice M. Voss, certify that:

     1.   I have reviewed this quarterly report on Form 10-Q of Front Range
          Capital Corporation;

     2.   Based on my knowledge, this quarterly report does not contain any
          untrue statement of a material fact or omit to state a material fact
          necessary to make the statements made, in light of the circumstances
          under which such statements were made, not misleading with respect to
          the period covered by this quarterly report;

     3.   Based on my knowledge, the financial statements, and other financial
          information included in this quarterly report, fairly present in all
          material respects the financial condition, results of operations and
          cash flows of the registrant as of, and for, the periods presented in
          this quarterly report;

     4.   The registrant's other certifying officer and I are responsible for
          establishing and maintaining disclosure controls and procedures (as
          defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the
          registrant and we have:

          a.   Designed such disclosure controls and procedures, or caused such
               disclosure controls and procedures to be designed under our
               supervision, to ensure that material information relating to the
               registrant, including its consolidated subsidiaries, is made
               known to us by others within those entities, particularly during
               the period in which this quarterly report is being prepared;

          b.   Evaluated the effectiveness of the registrant's disclosure
               controls and procedures and presented in this report our
               conclusions about the effectiveness of the disclosure controls
               and procedures, as of the end of the period covered by this
               report based on such evaluation; and

          c.   Disclosed in this report any change in the registrant's internal
               control over financial reporting that occurred during the
               registrant's most recent fiscal quarter that has materially
               affected, or is reasonably likely to materially affect, the
               registrant's internal control over financial reporting.


Date: November 10, 2005                 /s/ Alice M. Voss
                                        ----------------------------------------
                                        Alice M. Voss
                                        Chief Financial Officer
U. S. Department of Homeland Security 

 

 Office for Domestic Preparedness

 Washington, D.C. 20531 

ODP Information Bulletin 

No. 76 July 15, 2003

TO: All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

FROM: Andrew T. Mitchell 

 Acting Director 

SUBJECT: Submission of Categorical Assistance Progress Reports for Fiscal Year 2003 

 State Homeland Security Grant Program (SHSGP) - Part II Grants 

On March 21, 2003, the U.S. Department of Homeland Security (DHS), Office of State and 

Local Coordination (OSLC) requested that state and territorial Homeland Security Advisors 

report on steps taken to protect critical infrastructure during Operation Liberty Shield. This 

request focused on assets that fell into two categories: 1) those identified by DHS specifically; 

and, 2) those identified by the state based on an additional list of thirteen criteria provided by 

DHS. Forms for the submission of this data were provided by OSLC. 

As a reminder, this information MUST be included with the budget detail worksheets to be 

submitted with the SHSGP - II Categorical Assistance Progress Report due after June 30, 2003. 

The deadline for submitting these reports is July 31, 2003. Please remember special conditions 

requiring the submission of this information have been added to Fiscal Year 2003 State 

Domestic Preparedness Program (SHSGP) - Part II grants. Non-compliance with these 

requirements will result in withholding of funds. 

In addition to providing this information to the Office of the Comptroller, please also fax the 

completed Categorical Assistance Progress Reports and all associated attachments directly to the 

Office for Domestic Preparedness (ODP) at (202) 514-5566. Should you have any additional 

questions, please feel free to contact the ODP Helpline at: 1-800-368-6498.
| (logo) WELLS FARGO | **CMBS Department**

 

MAC N9401-011

1055 10th Avenue SE

Minneapolis, MN 55414 |
|--------------------|----------------------------------------------------------------------------------------|

 

Morgan Stanley Capital I Inc. 

1585 BROADWAY

NEW YORK, New York 10036-8200

 

RE: Annual Statement of Compliancefor Morgan Stanley Bank of America Merrill Lynch Trust 2013-C8, CommercialMortgage Pass-Through Certificates, Series 2013-C8

 

Per the Pooling and ServicingAgreement dated as of February 1, 2013 (the "Agreement"), theundersigned, a duly authorized officer of Wells Fargo Bank, N.A., as Custodian("Wells Fargo"), hereby certifies as follows as of and for the yearending December 31, 2016 (the "Reporting Period"):

 

(a) A review of Wells Fargo'sactivities during the Reporting Period and of its performance under theAgreement has been made under such officer's supervision; and

(b)  To the best of suchofficer's knowledge, based on such review, Wells Fargo has fulfilled all of itsobligations under the Agreement in all material respects throughout theReporting Period.

 

 

February 27, 2017

 

/s/ Gail Vannest

GAIL VANNEST

Vice President

 

 

 

| Wells Fargo Bank, N.A. |   |
|------------------------|--------|
<PAGE>   1
                                                                    Exhibit 5.1

                          [Perkins Coie LLP Letterhead]

                                December 3, 1998



Shurgard Storage Centers, Inc.
1155 Valley Street
Seattle, Washington  98109-4426

Gentlemen and Ladies:

        We have acted as counsel to you in connection with (i) the proceedings
for the authorization and issuance by Shurgard Storage Centers, Inc. (the
"Company") of up to 1,750,000 shares of the Company's 8.70% Series C Cumulative
Redeemable Preferred Stock, par value $0.001 per share (the "Series C Preferred
Shares"), together with an additional 250,000 shares if the underwriters
exercise an overallotment option (the "Overallotment Shares") and (ii) the
preparation and filing of a prospectus supplement to the Company's Registration
Statement on Form S-3, File No. 333-21273, which was declared effective by the
Securities and Exchange Commission on February 20, 1997 (the "Registration
Statement"), which you have filed with the Securities and Exchange Commission
with respect to the Series C Preferred Shares and the Overallotment Shares (the
"Prospectus Supplement").

        We have examined the Registration Statement, the Prospectus Supplement
and such documents and records of the Company and other documents as we have
deemed necessary for the purpose of this opinion.

        Based upon the foregoing, we are of the opinion that upon the due
execution by the Company and registration by its registrar of the Series C
Preferred Shares and the Overallotment Shares, and the sale of the Series C
Preferred Shares and the Overallotment Shares as contemplated by the
Registration Statement and the Prospectus Supplement and in accordance with the
applicable corporate, shareholder and governmental authorizations, the Series C
Preferred Shares and the Overallotment Shares will be duly authorized, validly
issued, fully paid and nonassessable.

        We hereby consent to the filing of this opinion as an exhibit to the
Form 8-K, and to the reference to our firm in the Prospectus Supplement and the
Registration Statement under the headings "Legal Matters."

                                      Very truly yours,

                                      PERKINS COIE LLP